A top Morgan Stanley sell-side analyst makes the jump from outside player to biotech C-suite insider
David Risinger spent more than 20 years observing the biopharma scene from the outside, spending the last 12 years at Morgan Stanley and ending as head of equity research on the Big Pharma front. Now, he’s making the leap to go inside biotech at one of the new startup plays by the buzzy Moderna founders at Flagship Pioneering.
Risinger this morning is formally leaving Morgan Stanley behind to become CFO at Cambridge, MA-based Cellarity, still in the early stages of assembling a pipeline based on the big-picture approach of studying cell behavior and then designing drugs around those insights — aided by some machine learning tech. Still preclinical, Cellarity has attracted Novartis vet Fabrice Chouraqui to the CEO suite and added a $123 million mega-round recently on top of its relatively small launch raise.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,300+ biopharma pros reading Endpoints daily — and it's free.